Bas Thijssen

606 total citations
21 papers, 461 citations indexed

About

Bas Thijssen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bas Thijssen has authored 21 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bas Thijssen's work include Colorectal Cancer Treatments and Studies (6 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cancer Treatment and Pharmacology (5 papers). Bas Thijssen is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cancer Treatment and Pharmacology (5 papers). Bas Thijssen collaborates with scholars based in Netherlands, Switzerland and Germany. Bas Thijssen's co-authors include Hilde Rosing, Jos H. Beijnen, Jan H.M. Schellens, Alwin D. R. Huitema, Robert S. Jansen, Ron J. Keizer, Liia D. Vainchtein, Serena Marchetti, Jeroen J. M. A. Hendrikx and Neeltje Steeghs and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Bas Thijssen

21 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bas Thijssen Netherlands 12 205 138 70 62 55 21 461
Shinji Kobuchi Japan 13 198 1.0× 122 0.9× 51 0.7× 60 1.0× 61 1.1× 61 529
Nilay Thakkar United States 9 198 1.0× 117 0.8× 37 0.5× 47 0.8× 52 0.9× 17 467
Daiki Tsuji Japan 14 159 0.8× 137 1.0× 51 0.7× 61 1.0× 63 1.1× 50 568
Takeshi Kotake Japan 15 123 0.6× 104 0.8× 106 1.5× 68 1.1× 34 0.6× 59 461
Andrew P. Beelen United States 12 235 1.1× 161 1.2× 115 1.6× 49 0.8× 25 0.5× 35 553
Svetlana Markova United States 3 196 1.0× 122 0.9× 30 0.4× 98 1.6× 32 0.6× 6 416
Martin Czejka Austria 15 245 1.2× 158 1.1× 61 0.9× 53 0.9× 80 1.5× 70 739
Venkateswaran C. Pillai United States 12 151 0.7× 106 0.8× 24 0.3× 68 1.1× 29 0.5× 22 487
Ryoichi Yano Japan 11 108 0.5× 115 0.8× 51 0.7× 42 0.7× 53 1.0× 31 376
G. Bastian France 12 237 1.2× 154 1.1× 65 0.9× 33 0.5× 28 0.5× 39 403

Countries citing papers authored by Bas Thijssen

Since Specialization
Citations

This map shows the geographic impact of Bas Thijssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bas Thijssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bas Thijssen more than expected).

Fields of papers citing papers by Bas Thijssen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bas Thijssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bas Thijssen. The network helps show where Bas Thijssen may publish in the future.

Co-authorship network of co-authors of Bas Thijssen

This figure shows the co-authorship network connecting the top 25 collaborators of Bas Thijssen. A scholar is included among the top collaborators of Bas Thijssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bas Thijssen. Bas Thijssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Verheijen, Remy B., Judith V.M.G. Bovée, Marta Fiocco, et al.. (2021). Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. Cancers. 13(22). 5780–5780. 2 indexed citations
4.
Weger, Vincent A. de, Julie M. Janssen, Marta López‐Yurda, et al.. (2021). Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours. Drugs in R&D. 21(1). 103–111. 4 indexed citations
5.
Thijssen, Bas, Hilde Rosing, Fabiana Alves, et al.. (2021). Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue. Journal of Pharmaceutical and Biomedical Analysis. 207. 114402–114402. 11 indexed citations
6.
Groenland, Stefanie L., Ruben A.G. van Eerden, Remy B. Verheijen, et al.. (2020). Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. Clinical Pharmacokinetics. 59(7). 941–948. 11 indexed citations
7.
Geel, Robin M.J.M. van, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens, et al.. (2020). Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. British Journal of Cancer. 122(8). 1166–1174. 27 indexed citations
8.
Thijssen, Bas, et al.. (2020). Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 185. 113245–113245. 8 indexed citations
9.
Huijberts, Sanne C.F.A., Robin M.J.M. van Geel, Emilie M.J. van Brummelen, et al.. (2020). Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemotherapy and Pharmacology. 85(5). 917–930. 26 indexed citations
10.
Brummelen, Emilie M.J. van, Sanne C.F.A. Huijberts, Carla M.L. van Herpen, et al.. (2020). Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The Oncologist. 26(4). 290–e545. 24 indexed citations
11.
Huijberts, Sanne C.F.A., Emilie M.J. van Brummelen, Carla M.L. van Herpen, et al.. (2020). Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.. Journal of Clinical Oncology. 38(15_suppl). 3613–3613. 1 indexed citations
12.
Weger, Vincent A. de, Frederik E. Stuurman, Stijn L.W. Koolen, et al.. (2019). A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir. Clinical Cancer Research. 25(18). 5466–5474. 16 indexed citations
13.
Weger, Vincent A. de, Frederik E. Stuurman, Jeroen J. M. A. Hendrikx, et al.. (2017). A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. European Journal of Cancer. 86. 217–225. 22 indexed citations
14.
Verheijen, Remy B., Bas Thijssen, Hilde Rosing, et al.. (2017). Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS. Therapeutic Drug Monitoring. 40(2). 230–236. 6 indexed citations
15.
Verheijen, Remy B., Sander Bins, Bas Thijssen, et al.. (2015). Development and Clinical Validation of an LC–MS/MS Method for The Quantification of Pazopanib in DBS. Bioanalysis. 8(2). 123–134. 17 indexed citations
16.
Keizer, Ron J., Robert S. Jansen, Hilde Rosing, et al.. (2015). Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research & Perspectives. 3(2). e00131–e00131. 151 indexed citations
17.
Marchetti, Serena, Frederik E. Stuurman, Stijn L.W. Koolen, et al.. (2012). Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 2550–2550. 10 indexed citations
18.
Hendrikx, Jeroen J. M. A., M. J. X. Hillebrand, Bas Thijssen, et al.. (2011). A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B. 879(28). 2984–2990. 41 indexed citations
19.
Vainchtein, Liia D., Hilde Rosing, Bas Thijssen, Jan H.M. Schellens, & Jos H. Beijnen. (2007). Validated assay for the simultaneous determination of the anti‐cancer agent gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma by high‐performance liquid chromatography with tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 21(14). 2312–2322. 30 indexed citations
20.
Vainchtein, Liia D., Bas Thijssen, Ellen Stokvis, et al.. (2005). A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. Biomedical Chromatography. 20(1). 139–148. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinji Kobuchi Breakdown of academic impact, for papers by Nilay Thakkar Breakdown of academic impact, for papers by Daiki Tsuji Breakdown of academic impact, for papers by Takeshi Kotake Breakdown of academic impact, for papers by Andrew P. Beelen Breakdown of academic impact, for papers by Svetlana Markova Breakdown of academic impact, for papers by Martin Czejka Breakdown of academic impact, for papers by Venkateswaran C. Pillai Breakdown of academic impact, for papers by Ryoichi Yano Breakdown of academic impact, for papers by G. Bastian
Rankless by CCL
2026